FDA clears Provalis' POC (point-of-care) diabetes monitor:
This article was originally published in Clinica
Executive Summary
UK company Provalis has received US FDA 510(k) clearance to market its point-of-care diabetes monitor. Glycosal, a simple four-minute test for glycated haemoglobin, can be used to help monitor the severity of diabetes and the effectiveness of long-term therapy. The device measures a diabetic's average level of glucose over the last three months by measuring a specific fraction of the patient's haemoglobin called HbA1c. Deeside-based Provalis said that the product is already available in over 20 markets in Europe, South America and the Far East. It will now apply for a CLIA waiver to bring the testing device to a larger market in the US.
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.